MCL1 and prostate carcinoma: In prostate cancer, Pasqualini et al.37 showed that miR-22 and miR-29a were less abundant in the cancerous tissue compared with the benign counterpart and functioned as tumor suppressors by modulating cancer associated targets LAMC1 and Mcl-1.